相关实验视频

Updated: Sep 13, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

在MET外显子14跳过非小细胞肺癌的患者中使用tepotinib

Paul K Paik¹, Wade T Iams², Hatim Husain³

¹Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.

Cancer treatment reviews

|July 30, 2025

概括

德波提尼布为非小细胞肺癌 (NSCLC) 提供有效的口服治疗,其中MET外显子14跳转. 视觉研究证实了其持久的疗效,特别是在第一线治疗中,在各种患者群体中.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
遗传学遗传学是一个

背景情况:

非小细胞肺癌 (NSCLC) 管理正在通过向疗法发展.
在3-4%的NSCLC患者中,MET外显子14 (METex14) 跳过是可采取行动的驱动因素.
德波提尼布为这种预后不佳的患者群体提供口服的向治疗.

研究的目的:

审查关于tepotinib的已发表文献.
详细介绍tepotinib的作用机制和药理学.
分析二期VISION研究对METex14跳过NSCLC中的tepotinib的数据.

主要方法:

关于tepotinib的出版文献的审查.
分析了第二阶段VISION研究中的数据.
检查子组分析,长期结果和生物标志物数据.

主要成果:

在VISION研究中,特波提尼布表现出强大而持久的疗效,特别是在一线设置中.
在各种子组中观察到一致的疗效,包括年龄,种族和大脑转移的存在.
这项研究支持全球监管机构对tepotinib的批准.

结论:

德波提尼布是一种有效的针对性治疗NSCLC与METex14跳转.
该VISION研究提供了强有力的证据证明tepotinib的有效性,并支持其在临床实践中的使用.
讨论了进一步了解长期结果,治疗顺序和不良事件管理.

关键词:

在MET外,第14节跳过.转基因转基因抑制剂的使用非小细胞肺癌是非小细胞肺癌.德波提尼布 (Tepotinib) 是一种药物.治疗顺序的顺序处理.

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...